Although several centers are now performing allogeneic hematopoietic SCT (HSCT) in the Eastern Mediterranean (EM) region, the availability is still limited. Special issues including compatible donor availability and potential for alternative donor programs are discussed. In comparison to Europe and North America, differences in patterns of diseases and pre-HSCT general status, particularly for patients with BM failure, are described. Other differences including high sero-positivity for CMV, hepatitis B and C infection, and specific observations about GVHD and its relation to genetically homogeneous communities are also discussed. We report that a total of 17 HSCT programs (performing five or more HSCTs annually) exist in 9 countries of the EM region. Only six programs are currently reporting to European Group for Blood and Marrow Transplantation or Center for International Blood and Marrow Transplantation Research. A total of 7617 HSCTs have been performed by these programs including 5701 allogeneic HSCTs. The area has low-HSCT team density (1.56 teams per 10 million inhabitants vs 14.43 in Europe) and very low-HSCT team distribution (0.27 teams per 10 000 sq km area vs o1-6 teams in Europe). Gross national income per capita had no clear association with low-HSCT activity. Much improvement in infrastructure and formation of an EM regional HSCT registry are needed.
Introduction
Hematopoietic SCT (HSCT) is a life-saving treatment for many diseases. However, because of the relatively high cost and the need for a multi-disciplinary team and advanced laboratory support, limited numbers of centers in the developing world are providing this modality of treatment.
High-quality data about HSCT activity are widely available through the European Group for Blood and Marrow Transplantation (EBMT) and the Center for International Blood and Marrow Transplantation Research (CIBMTR). However, both registries contain more data from centers located in Western Europe and North America.
Although the number of centers performing allogeneic HSCT in the Eastern Mediterranean (EM) region as defined by the World Health Organization (WHO) 1 ( Figure 1 ) has increased, there are no data available currently about the transplant activities in this region or the issues related to HSCT in the listed countries.
During the last year, a collective effort has been carried out through program representatives in the EM region with the goal of simple identification of issues related to HSCT in the EM area and to conduct the first survey ever done for this region. This is a part of an ongoing collective effort by the programs in the region to ultimately establish an EM HSCT organization with the help of the EBMT, the CIBMTR and in collaboration with the World Bone Marrow Transplantation Group.
Methods
All programs in the WHO-designated EM region with consistent annual performance of X5 cases per year for at least 3 consecutive years were identified and included. Programs from each country were asked to submit a standardized report to include the following information:
1. Total population and Gross National Income (GNI) As far as possible, the EBMT Group Activity Survey was used as a template for analysis of the activity data, and supplementary data were obtained from EBMT and CIBMTR as necessary.
HSCT 'team density' was calculated as the number of HSCT teams per 10 million inhabitants in each country. HSCT 'team distribution' was calculated as the number of transplant teams per 10 000 sq km area in each country. 
Results
The EM region has a total of 21 countries with a total population of more than 540 million. These 21 countries include 1 country with low-income category, 5 with lower middle-income category, 8 with upper middle-income category and 7 with high-income category countries according to WHO income groups based on GNI per capita. Only 9 of the 21 countries (70.8% of the total EM region population) have at least one active HSCT programs available for their population ( Table 1 ). The total number of programs existing at present is 17. Unfortunately only 6 of this 17 report data to EBMT and/or CIBMTR. Table 2 lists the number of patients who received allogeneic or autologous HSCT in the nine countries and some of the main issues related to HSCT in each country, [2] [3] [4] [5] [6] [7] [8] which will be discussed in detail below along with the economic-logistic indices related to the HSCT activity, team density and team distribution in this region. Overall, it is easy to comprehend that although the rate of transplantation has generally increased over the last 5 years, the ratio of transplantation to the total population of the individual country has remained low.
The specific issues related to allogeneic HSCT in the EM region can be divided into donor availability, genetic issues, issues related to specific diseases, pattern of infections and logistics. Each is discussed below in detail.
Donor availability
The EM region consists of communities of large families with high-population growth, which certainly increases the likelihood of finding a fully HLA-matched sibling donor. For example, the reported likelihood of finding a fully matched sibling donor in Saudi Arabia is 63.5%, 9 whereas the number can be as high as 70% in some areas in Pakistan.
2 This is far higher than the likelihood of finding a sibling donor for European and North American patients. Additionally, the overall outcome of class I antigen mismatch sibling allogeneic transplantation yields a similar result as for full-matched sibling transplantation, which is likely to reflect ethnically and genetically the homogenous make-up of the population. This leaves a smaller percentage of patients requiring an alternative donor source for their transplantation. A lower occurrence of acute and chronic GVHD (cGVHD) has also been observed. [10] [11] [12] [13] This has also been supported by similar observations made in larger studies comparing the risk of GVHD in different ethnic populations. 14 The lower occurrence of cGVHD may have an obvious impact on diseases that are susceptible to GVL effects such as CML and diseases with a lowproliferation rate. Cord blood transplantation remains the preferred alternative donor transplantation modality in the centers that offer alternative donor HSCT. This is because of the relatively lower likelihood of finding a match through Western unrelated donor registries and the logistic difficulties in timely performance of HSCT from matched unrelated donors, typically available in Western Europe and North America.
Polymorphism of genes
Knowledge of the prevalence of polymorphism in certain genes, such as cytokine genes, related to the risk of development of GVHD, as well as genes coding for enzymes responsible for drug metabolism, is badly needed in certain communities with high likelihood of consanguinity, and in the EM region at large. Inactivating mutations have been found in genes coding for enzymes belonging to the cytochrome P-450 system, and also in genes coding for other enzymes. A local pharmacogenomic study from Saudi Arabia has shown a unique profile of variations in metabolism genes in Arab population. 15 PCR analysis revealed that the frequencies of alleles and/or genotypes for CYP1A1 2A, GSTT1 null, GSTT1 and GSTM1 double null, and GSTP1 A1578G in Arabs were significantly higher than those reported in Caucasians. 15 Other alleles in Arabs, including CYP1A1 T3801C and GSTP1 A1578G were present in frequencies similar to Africans. 15 Several pharmacogenomic research projects are being pursued in the EM countries in relation to this matter.
Disease-specific issues
Severe aplastic anemia. A higher proportion of patients with severe aplastic anemia in the EM were heavily pretransfused when referred for allogeneic HSCT. Accordingly, a strong lymphoablative component always has to be included in the conditioning chemotherapy to avoid graft rejection. Fludarabine is being increasingly utilized as a lymphoablative component, traditionally with CY for conditioning of aplastic anemia patients. The major reason for the emerging utilization of fludarabine as the lymphoablative component is the prohibitive cost of anti-thymocyte globulin in addition to the lower likelihood of side effects with fludarabine, particularly in older patients. Large Table 1 Eastern Mediterranean region countries 1 -populations and status of HSCT programs. numbers of aplastic anemia patients are referred to the transplant centers with a variety of infections including viral, bacterial and fungal infections. Recently, availability of new generation anti-fungal therapies has led to a dramatic improvement in the outcome of patients with fungal infections. Sometimes, short-term use of these combined drugs to treat proven fungal infection facilitates the timely performance of transplantation procedures. However, these new generation anti-fungal drugs are neither universally available nor affordable for all centers in the area. A small but a definite subset of patients presents with elevated liver enzymes on admission, some with positive hepatitis serology. However, a small but definite subset of patients has 'sero-negative hepatitis aplasia syndrome' similar to that described in earlier reports. 16, 17 These patients with negative hepatitis serology tend to respond to treatment with immunosuppression therapy only.
Country Population
Congenital BM failure syndromes and hemoglobinopathies. Marital consanguinity is highly prevalent in the EM countries, and consequently there is a high prevalence of hemoglobinopathies including thalassemia and sickle cell anemia. 4, 6, 7 Patients with hemoglobinopathies and BM failure syndromes are typically heavily pretransfused before they are transferred to the transplant centers, and consequently these patients are iron overloaded and frequently have positive serology for hepatitis B and/or C virus. Collectively, all these factors are a set-up for organ dysfunction and transplantation complications, most notably hepatic veno-occlusive disease. Despite all these limitations, non-neoplastic indications for allogeneic HSCT remain one of the main reasons for HSCT in certain EM transplantation centers. This is particularly common in countries where there is significant case attrition for acute leukemias because of the suboptimal set-up conditions for chemotherapy induction in the referring centers.
2,3
Chronic myeloid leukemia. With the availability of tyrosine kinase inhibitor therapy, allogeneic HSCT is no longer offered as a first-line treatment option for CML patients in first chronic phase, as is now also accepted practice in other centers worldwide. 18 This is true for centers where tyrosine kinase inhibitor therapy is available. However, in countries where tyrosine kinase inhibitor therapy is not available because of its prohibitive costs, or in situations where the physician is unable to rely on continuation of the medication supply, the physician faces the dilemma of choosing the best management strategy available to the patient and not the best treatment strategy in absolute terms. Accordingly, allogeneic HSCT for CML in first chronic phase remains more cost effective as once in a lifetime procedure and one of the main indications for transplantation in some centers. This is also related to the fact that CML patients do not need an urgent transplantation and are frequently in optimal physical condition to undergo such a procedure. This is in contrast to acute leukemias, where timely transplantation is needed and where the patient is in less optimal shape to survive the procedure. In a few countries, generics of tyrosine kinase inhibitor are widely available at a very affordable cost. However, for majority of countries, the medication has to be purchased at the standard price with no significant price adjustment based on the per capita income of each country. The issue of lower incidence of cGVHD is an issue of great relevance in relation to the risk of relapse in CML. Accordingly, many centers are practicing early reduction and discontinuation of post HSCT immunosuppression for patients with no history of acute GVHD in attempt to induce a limited de novo cGVHD to promote the development of GVL.
AML. An important requirement for offering allogeneic HSCT for patients with acute leukemias is the capability, both financially and logistically, of achieving CR through induction chemotherapies. At some centers in the EM region this becomes one of the competing factors for the limited slots for allogeneic HSCT and eventually benign conditions, such as aplastic anemia and thalassemia (not requiring daunting cost and support for induction chemotherapy), disproportionately become leading indication for allogeneic HSCT. 2, 3 Another interesting regional observation is the relatively poor outcome of AML with t(8; 21), which is generally considered favorable. Unpublished data from King Faisal Specialist Hospital and Research Center in Riyadh suggested the EFS of this leukemia with standard induction and high-dose cytarabine chemotherapy consolidation is 16%. The relatively more aggressive behavior of AML with t(8; 21) has been reported in South-East Asia. 19 The observed lower outcome of management of this leukemia in non-whites in North American data also suggested that the behavior of this disease is not consistently favorable, possibly related to different breakpoints or expression of other biologic and/or molecular markers that are known to be associated with poor prognosis. 20, 21 Lymphoid malignancies. It is well established that the incidence of indolent lymphoid malignancies decreases as one moves east across the globe. A relatively higher percentage of intermediate-and high-grade lymphoma is observed in the EM and, accordingly, a relatively high proportion of eligible patients with the latter two entities are being transplanted compared with Western Europe and North America. 22 Issues related to Infections CMV infection. High levels of sero-positivity for CMV was reported in many countries in the EM region reflecting high rate of previous exposure to this virus. The reported sero-positivity was 100% among the recipients and 96% among donors in Saudi Arabia, 23 and 100% in donors and recipients in Pakistan. 2 These data are also consistent with reports from India. 24 There are several strategies for the prevention of CMV disease in high sero-prevalence set-up that apply to the EMRO region. On one hand, adequate pre-emptive therapy can be based on early detection of CMV infection and on the other hand the pre-emptive therapy need not to be continued for any extended period beyond establishment of CMV antigen negativity to prevent interference with the development of CMV-specific immune reconstitution.
23,25
Hepatitis B virus infection. The endemicity of hepatitis B virus (HBV) in the EM region is well established. [26] [27] [28] According to a report 28 HBV reactivation may also be an additional risk factor in causation of veno-occlusive disease and other related complications. Another problem is encountered when the only matched donor is hepatitis B surface antigen-positive and HSCT needs to be carried out for an urgent indication. It is to be noted that the availability of lamivudine and other effective therapies for HBV had remarkably improved the outcome of allogeneic HSCT with HBV-positive recipient and/or donor during the last decade.
Hepatitis C virus infection. Hepatitis C virus (HCV) remains a major disease burden in the EM region. Prevalence rates across the world have changed with increased awareness about transfusion-related hepatitis C Special issues in HSCT in the Eastern Mediterranean region MD Aljurf et al and more and more evidence supporting intravenous illicit drug use as the leading risk factor for the spread of virus. 30 A high-prevalence rate of HCV has been reported in Egypt in the recent past (up to 28% in some groups). 31 Lower rates have been reported among blood donors from various regions of Saudi Arabia (0.4-4.3%) 32, 33 and in Yemeni patients (2.1%). 34 HCV has six genotypes with numerous subtypes. Depending on the HCV genotype, length of the treatment can differ. Genotype 1b is less responsive to a-interferon therapy when compared with genotypes 2 and 3. Genotype 4 is the most common genotype in the EM region, 30, 33, [35] [36] [37] [38] which unfortunately is least likely to respond to the standard interferon therapy, though recent studies using pegylated interferon showed better results. A recent multicenter national study from Saudi Arabia on patients with HCV showed that 59.6% had genotype 4, 25.1% had genotype 1, 8.3% had genotype 2 and 6.4% had genotype 3. 38 However, distribution of HCV genotypes is not uniform in the EM region, for example, Iran has a major prevalence of HCV genotype 1 (55.8% cases). 39 Traditionally, HCV is known to have less contribution to early post transplant morbidity and mortality, but obviously is likely to cause complications later in life such as liver cirrhosis. Difficult situations sometimes exist, where the only matched donor is hepatitis C antibody positive, and allogeneic HSCT is urgently needed such as in cases of acute leukemia or aplastic anemia.
Mycobacterium tuberculosis. Although mycobacterium tuberculosis is relatively an endemic disease in certain areas of EM, the likelihood of reactivation after HSCT is less frequent than what would be expected in an endemic area. Additionally, the likelihood of reactivation after HSCT is less than the reported rate of activation after transplantation for solid organs in the same set-up. 40 As a significant proportion of the population, especially older individuals, has a positive purified protein derivative (PPD) status either from previous exposure or BCG vaccination in childhood, the appropriateness of the universal routine prophylaxis with isoniazid (isonicotinyl hydrazine (INH)) for PPD-positive HSCT recipient who has a low likelihood of re-activation will be questioned. Accordingly, many centers in the EM believe that prophylaxis with INH in PPD-positive patients should not be given routinely for patients who are completely asymptomatic with negative chest X-ray, which otherwise would expose the majority of patients to potential hepatotoxic medication that has many potential drug interactions with other medications used during HSCT. This practice may not be in line with the published Centers for Disease Control and Prevention guidelines 41 regarding infection prophylaxis in HSCT, but is substantiated by our observations in the EM region. 2 Other Infections. High prevalence of schistosomiasis in Egypt 42 and endemicity of malaria in certain areas of Pakistan 43 are well documented. Relevantly, poor malaria screening of asymptomatic blood donors led to some incidences of transfusion-transmitted malaria in HSCT recipients during the early transplant period in Pakistan. 2 In Egypt, the relative risk of developing veno-occlusive disease after allogeneic HSCT was calculated to be 16.8-fold higher in patients with previous history of schistosomiasis. 42 Logistic issues important to the EM region Reports from the EBMT and CIBMTR have illustrated earlier that the number of transplants differ significantly between countries. 44 This is true for all regions, but no detailed information is available about the EM region.
By tradition, some EBMT reports include data from a few non-European countries that fall in the EM region (Iran, Saudi Arabia and Tunisia) and report their HSCT activity to EBMT registry. Their data are in part included in some of the analyses. Hence, data published by the EBMT group may also be informative for patients' counseling and decisions made by health care professionals, planners and administrators in the EM region. However, more detailed information specific to this region is desirable. 45 The EBMT has analyzed factors associated with differences in HSCT activity between the participating teams from more than 240 countries over a time span of 15 years. Results have revealed that GNI per capita, numbers of transplant teams per 10 million inhabitants or per 10 000 km, team size and team experience all had an impact on transplant activity. 46 Moreover, it was realized that some other factors might have been involved in the decisions to perform or not to perform HSCT.
The recent EBMT report based on the activity survey for 2006 47 shows that transplant rates predictably increased over time with nearly linear trends, in clear association with GNI per capita and distinctly by the World Bank income category within a narrow window of variation for both autologous HSCT and allogeneic HSCT when breast cancer (autologous) and CML (allogeneic) were excluded. 47 Team density and team distribution were also associated with transplant rates. 47 Table 3 summarizes the various factors that affect HSCT activity in European countries as reported by the EBMT group. 47, 48 These included economic factors such as GNI per capita or health care expenditures per capita, team density and team distribution. There were also clear differences in transplant rates for certain disease indications, which might relate to a different prevalence of the disease, for example hemoglobinopathies. Table 3 Factors associated with differences in transplant rates between European countries 40, 41 
47,48

Economic factors
Gross national income per capita Health care expenditures per capita Health care system
Logistic factors Team density Team distribution
Local factors
Our preliminary findings reported here are based on cumulative experience of 17 teams in 9 countries of the EM region over the last two decades. Of the 17 teams, 16 (94%) performed both allogeneic and autologous HSCT and 1 (6%) restricted its activity to autologous HSCT only.
Team density in the EM region is very low (1.56 compared with 13.43 in Europe) 48 and HSCT team distribution in the countries where significant HSCT exists is also very low (0.27) in comparison to European countries where it ranges from o1 to 6 teams per 10 000 sq km area. 47, 49 Figure 2 shows that the total HSCT performed to date in the reported countries of the EM region is quite variable. HSCT teams in Saudi Arabia, Iran and Egypt have exceeded 1000 transplants. Figure 3 displays GNI per capita-based WHO income categories in the EM region. Most of the reported countries are in the upper middleincome category, except Saudi Arabia and Oman, which are in the high-income group and Pakistan in the lower middle-income category. Figure 4 reflects low-HSCT team densities in most of the EM region, except one relatively small country (Lebanon) with a density of 4.93. These numbers are very low compared with European data. Table 4 shows HSCT activity and the related economiclogistic indices in the EM region. It is evident that more than the GNI per capita (which is not easily changeable factor), team densities and team distribution need special attention from health care planners. 47 Currently, a good but uncertain number of patients from the EM region, especially from countries with WHO high-income category, are referred to the United States or Western Europe for HSCT. However the authors have no estimates of such referrals. Such cases are mostly sponsored by the state, charity support or family resources.
For comparison, the EBMT data based on a 15-year observation period within the EBMT activity survey show that transplant rates in Europe are highly predictable, show a clear association with GNI per capita and are distinct in their evolution by the World Bank income category. 47 These data indicate that although transplant teams do their best to meet the needs, they still fail to do so. They are limited by resources, as illustrated by the clear association of transplant rates with GNI per capita and the World Bank income category. 47 EBMT data and our initial findings indicate that HSCT activity is also limited by the infrastructure, as documented by the association between transplant activity, team density and team distribution. 48 The countries in the EM region lacking significant HSCT activity suffer from limited economic resources and/or lack of expertise and logistic support. In addition, more curable and more prevalent health problems may be competing for the limited resources in lower income category countries. A significant number of patients are referred from the EM region, especially from countries with WHO high-income category, to the United States or Western Europe for HSCT. However, as noted above, the authors have no estimates of such referrals. Obviously, the programs offering HSCT facilities in the region are unable to meet the needs of the patients from their respective countries. Hence the desirable referral between countries of the EM region is not yet fully developed, although such a referral system may help those EM countries, who particularly have no internal access to HSCT. Practically, it will be more prudent to help such countries in establishing their own HSCT centers through collaboration, training and outreach programs, such as those offered by EBMT to develop the medical and nursing workforce.
This report is based on initial data from the EM region, which is obviously limited. Recent EBMT analysis on predictability of HSCT rates 47 also had some limitations. Firstly, there is no uniform database on the incidence or prevalence of the individual disease categories in the participating countries. Secondly, data were limited to Europe and it is difficult to extrapolate the conclusions to other continents. Nevertheless, it is likely that similar factors, such as GNI per capita and team density also affect transplant rates in the EM region. It is also likely that considerations on cost-effectiveness will affect decisions between HSCT and lifelong expensive therapies in countries of the EM region (CML being a typical example). 50, 51 Most of the EM region countries have health care systems, supported economically by the state, as is the case in the Europe. If HSCT is performed in a private center, the procedure cost is paid by the patient in full, or in part with the remainder being paid by charity resources. Most countries lack health care insurance systems covering the cost of HSCT procedure, making HSCT a financial ordeal for the patient and family.
It is clear that the need for HSCT will continue to increase in the near future. Improvement in supportive care and antimicrobial therapy, increasing donor pools worldwide, increasing availability of cord blood products and novel conditioning regimens should provide access to HSCT for patients not considered earlier as candidates for these procedure. 1 Health care providers in the EM region will face this complex problem and they should initiate rigorous actions to put the infrastructure in place.
It is important to find the correct balance between a restricted number of HSCT teams (that they have sufficient expertise and quality of service) and an adequate number in order to guarantee access for all patients, independently of travel distances. Above all, there is no indication of an abundance of transplant beds. There is a need to provide infrastructure for more HSCT centers. The anxiety of health care agencies fearing over-abundance of HSCT centers (owing to the example of CML) now seems unnecessary and they can be reassured that trends, with the advent of novel therapies which affect the demand for HSCT, are recognized in a timely fashion. With up-to-date instruments, such as the EBMT activity survey, changes in therapy can easily be recognized at an early stage and appropriate measures can be taken to curtail the feared unnecessary growth of HSCT centers. These data clearly illustrate the need for more research to understand the mechanism of HSCT activity and into the mechanisms of technology dissemination in the EM region.
If possible, such studies should be performed on a wider collaborative basis. This appears essential to enable health care agencies to provide adequate infrastructure for this high-cost procedure, especially in the EM region and other developing countries.
To improve HSCT activity-related performance standards, acquisition of Foundation for the Accreditation of Cellular Therapy (FACT) and Joint Accreditation Committee of the ISCT-EBMT (JACIE) accreditation by the centers in the EM region will obviously be helpful. However, potential logistic hurdles in accreditation related to transplant volumes, access to collection and processing facilities, and geographical factors might present challenges. Moreover, such requirements for accreditation may result in rationalization of health resources into centers capable of achieving accreditation where resources are limited. On the other hand, mandatory application of accreditation requirements, at least in the beginning, may challenge the efforts to establish new centers with already limited enthusiasm and resources.
Severe shortage of trained personnel in the field of HSCT at all levels mandates the need for an EM HSCT League to promote recent technologies and improve experience related to HSCT in the region. Formation and identification of a regional HSCT training center for nurses, physicians, coordinators, researchers, data base instructors and so on will be highly instrumental in accomplishing this goal. This will be a source of exchanging experiences, providing training for new centers and also serves as a reference for standardization of procedures. Other strategies may include initiating an EM 'Nursing Board' to manage the problems related to paramedical manpower, updating HSCT procedures and increasing awareness about HSCT among the staff and the patients.
Other issues
Options for fertility preservation in the EM region are limited and are not optimally discussed with the patient and family due to other priorities competing for the resources and cultural issues related to scarcity of credible sperm banking facilities. Such facilities need to be built and strictly regulated, as concept of surrogate sperm donor is socially not acceptable in most of the EM region.
Others areas that need improvement, as mentioned earlier in the paper, include wider availability of alternative donor sources for the minority of patients who do not have matched sibling donors, and the necessity of national and regional registries of donors to make a larger pool of genetically similar donors available. Initiation of Regional Cord Blood Banks, which should offer a great potential for suitable alternative donors in an area where childbearing potential is high and many HLA antigens are expected to cluster, will minimize the incidence of not finding a matched donor.
Leading teams in the EM region are now working to establish their own national cord blood and unrelated donor programs.
Finally, a regional HSCT registry will be a step forward in promoting allogeneic HSCT in the EM region, identifying other regional problems and may also be helpful in benchmarking HSCT outcomes. A study from the United Kingdom and Ireland recently compared their data with the EBMT and showed the potential for using national registries to benchmark transplant outcome using EBMT registry as reference. 52 
